

DEPARTMENT OF VETERANS AFFAIRS

**Justification for Single Source Awards IAW [FAR 13.106-1](#)
For
Over Micro-Purchase Threshold but Not Exceeding the SAT (\$150K)**

Acquisition Plan Action ID: **VA255-18-AP-1231**

1. Contracting Activity: *Department of Veterans Affairs, VISN 15, St. Louis VA Medical Center - Research Department. NCO-15, Leavenworth KS. 66048*

2. Brief Description of Supplies/ Services required and the intended use/Estimated Amount:
*HCVD2MAG-67K-10 Milliplex human CVD panel 2, magnetic, 10-plex complete panel
HCVD3MAG-67K-06 Milliplex human CVD panel 3, magnetic, 6-plex for CRP, Fibrinogen, Haptoglobin, PlateletFactor 4, Serum Amyloid P and von Willebrand Factor
HCYTOMAG-60K-17 Milliplex human cytokine panel 1, magnetic, 16-plex for Fractalkine, G-CSF, GM-CSF, IFN α 2, IFN γ , IL-1 α , IL-1 β , IL-1 α , IL-3, IL-6, IL-8, IL-10, MCP-1, MIP-1 α , TNF α , TNF β , and VEGF-A*

These panels contain beads that bind to specific cytokines and inflammatory markers. The goal is to identify cytokines and other inflammatory markers that are present in pericardial fluid in order to determine if they are associated with postoperative atrial fibrillation. We need the above Luminex beads in order to accomplish this task.

3. Unique characteristics that limit availability to only one brand, with the reason no other supplies or services can be used: *Only the kits sold by MilliporeSigma will work with the existing Milliplex equipment. Obtaining different brand will require purchasing a complete new system and retraining of personnel.*

4. Description of market research conducted and results or statement why it was not conducted:

5. Contracting Officer's Certification: *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Note: COs are required to make a determination of price reasonableness IAW FAR 13.106-3. See the S19 Open Market (FAR13) Award Documentation Form with Abstract to document price reasonableness.*

Submitted by: Emilio Ballentos

December 11, 2017

Reviewed by:

**Yvonne Kittling
Contracting Officer**

Date